Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Calithera Biosciences is a pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer.
Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.
Immunitas Therapeutics is a single cell genomics-based drug discovery company that modulates oncology targets.
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
Verastem is a biopharmaceutical company developing new medicines to improve the lives of patients with RAS/MAPK pathway-driven cancers.
AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders.
Vertero Therapeutics is using cutting-edge research outside of the brain to treat neurodegenerative illnesses.
Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout.
KalVista Pharmaceuticals is an ophthalmology company focused on developing drugs for the treatment of diabetic macular edema (DME).
Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.
Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
XyloCor Therapeutics is a biopharmaceutical company intended to develop gene therapy for people with coronary artery disease.
Interius BioTherapeutics is a biotechnology company that delivers genetic medicines for patients.
Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.
Tome Biosciences is a biotechnology company that develops programmable gene insertion technology.
Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation.
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.
DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints.
Carbon Biosciences is a biotech company that engages in the novel parvovirus gene therapy.
ImmuneID is a precision immunology company that provides a technological platform to deliver insights into the human immune response.
Longwood Fund has invested in 56 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Longwood Fund's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Life Science. The firm invests across 14 different industry categories.
Among tracked funding rounds, Tome Biosciences received $213.0M in a Series A round. Longwood Fund's total known invested capital is $4.3B.
Longwood Fund's average investment size is $77.3M across its portfolio of 56 companies.
Recent Longwood Fund portfolio additions include Werewolf Therapeutics, Calithera Biosciences, Rectify Pharmaceuticals, Immunitas Therapeutics, Mediar Therapeutics. These companies were founded in 2020 or later.